These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38034413)

  • 1. Efficient regulatory approval of two novel HIV prevention interventions in a resource-limited setting: experiences from Zimbabwe.
    Murombedzi C; Chirinda L; Chareka GT; Chirenje ZM; Mgodi NM
    Front Reprod Health; 2023; 5():1279124. PubMed ID: 38034413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promises and potential pitfalls of long-acting injectable pre-exposure prophylaxis.
    Pike C; Rousseau E; Bekker LG
    South Afr J HIV Med; 2023; 24(1):1497. PubMed ID: 38089889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Acting Injectable Cabotegravir for HIV Preexposure Prophylaxis Among Sexual and Gender Minorities: Protocol for an Implementation Study.
    Grinsztejn B; Torres TS; Hoagland B; Jalil EM; Moreira RI; O'Malley G; Shade SB; Benedetti MR; Moreira J; Simpson K; Pimenta MC; Veloso VG;
    JMIR Public Health Surveill; 2023 Apr; 9():e44961. PubMed ID: 37074775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Shaping and coordinating the implementation science agenda for injectable cabotegravir for PrEP: the role of the Biomedical Prevention Implementation Collaborative (BioPIC).
    Warren M; Nyagah W; Verde Hashim C; Rodolph M; Schaefer R; Schmidt HA; Baggaley R
    J Int AIDS Soc; 2023 Jul; 26 Suppl 2(Suppl 2):e26094. PubMed ID: 37439050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Securing accelerated access to long-acting injectable cabotegravir for HIV prevention in low- and middle-income countries.
    Jenkins SY; Resar D; Panos Z; Staple A; Watkins M; Ripin D; Amole C
    J Int AIDS Soc; 2023 Jul; 26 Suppl 2(Suppl 2):e26101. PubMed ID: 37439082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-acting injectable cabotegravir for PrEP: A game-changer in HIV prevention?
    Liegeon G; Ghosn J
    HIV Med; 2023 Jun; 24(6):653-663. PubMed ID: 36468218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Personalizing prevention: Advances in pharmacotherapy for HIV prevention.
    Brizzi M; Sherman EM; Green SB; Nowicki DN; Drwiega EN; Nicol MR; Chastain DB; Sahloff EG; Truong WR; Cluck D; Badowski ME; Michienzi SM; Durham SH
    Pharmacotherapy; 2023 Apr; 43(4):305-320. PubMed ID: 36938645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cabotegravir: The First Long-Acting Injectable for HIV Preexposure Prophylaxis.
    Durham SH; Milam A; Waer D; Chahine EB
    Ann Pharmacother; 2023 Mar; 57(3):306-316. PubMed ID: 35778802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of long-acting injectable cabotegravir as preexposure prophylaxis to prevent HIV acquisition.
    Fonner VA; Ridgeway K; van der Straten A; Lorenzetti L; Dinh N; Rodolph M; Schaefer R; Schmidt HA; Nguyen VTT; Radebe M; Peralta H; Baggaley R
    AIDS; 2023 May; 37(6):957-966. PubMed ID: 36723489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advancing the use of Long-Acting Extended Delivery formulations for HIV prevention in sub-Saharan Africa: challenges, opportunities, and recommendations.
    Mgodi NM; Murewanhema G; Moyo E; Samba C; Musuka G; Dzinamarira T; Brown JM
    J Int AIDS Soc; 2023 Jul; 26 Suppl 2(Suppl 2):e26115. PubMed ID: 37439069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cabotegravir Extended-Release Injectable Suspension: A Review in HIV-1 Pre-Exposure Prophylaxis.
    Blair HA
    Drugs; 2022 Sep; 82(14):1489-1498. PubMed ID: 36255686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Introducing the Dapivirine Vaginal Ring in Sub-Saharan Africa: What Can We Learn from Oral PrEP?
    Bhavaraju N; Shears K; Schwartz K; Mullick S; Jeckonia P; Murungu J; Persaud U; Vij A; Torjesen K
    Curr HIV/AIDS Rep; 2021 Dec; 18(6):508-517. PubMed ID: 34910276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Acting Injectable Drugs for HIV-1 Pre-Exposure Prophylaxis: Considerations for Africa.
    Moyo E; Murewanhema G; Musuka G; Dzinamarira T
    Trop Med Infect Dis; 2022 Jul; 7(8):. PubMed ID: 36006246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Layer Plus Approach to Implementation Research and Collaboration for Long-Acting Injectable Preexposure Prophylaxis for HIV Prevention.
    Pilgrim NA; Evans TM; Czarnogorski M
    Health Promot Pract; 2022 Nov; 23(6):912-915. PubMed ID: 35713273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States : A Cost-Effectiveness Analysis.
    Neilan AM; Landovitz RJ; Le MH; Grinsztejn B; Freedberg KA; McCauley M; Wattananimitgul N; Cohen MS; Ciaranello AL; Clement ME; Reddy KP; Hyle EP; Paltiel AD; Walensky RP
    Ann Intern Med; 2022 Apr; 175(4):479-489. PubMed ID: 35099992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the registration process of the medicines control authority of Zimbabwe with Australia, Canada, Singapore, and Switzerland: benchmarking best practices.
    Sithole T; Salek S; Mahlangu G; Walker S
    Expert Rev Clin Pharmacol; 2022 Jan; 15(1):109-119. PubMed ID: 34645359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating the potential impact and cost-effectiveness of dapivirine vaginal ring pre-exposure prophylaxis for HIV prevention.
    Reidy M; Gardiner E; Pretorius C; Glaubius R; Torjesen K; Kripke K
    PLoS One; 2019; 14(6):e0218710. PubMed ID: 31242240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M).
    Chounta V; Overton ET; Mills A; Swindells S; Benn PD; Vanveggel S; van Solingen-Ristea R; Wang Y; Hudson KJ; Shaefer MS; Margolis DA; Smith KY; Spreen WR
    Patient; 2021 Nov; 14(6):849-862. PubMed ID: 34056699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV prevention at drug shops: awareness and attitudes among shop dispensers and young women about oral pre-exposure prophylaxis and the dapivirine ring in Shinyanga, Tanzania.
    Tubert J; Packel L; Hunter LA; Mfaume R; Njau P; Ramadhani AA; Liu JX; McCoy SI
    AIDS Res Ther; 2021 Apr; 18(1):21. PubMed ID: 33902623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial.
    Landovitz RJ; Li S; Grinsztejn B; Dawood H; Liu AY; Magnus M; Hosseinipour MC; Panchia R; Cottle L; Chau G; Richardson P; Marzinke MA; Hendrix CW; Eshleman SH; Zhang Y; Tolley E; Sugarman J; Kofron R; Adeyeye A; Burns D; Rinehart AR; Margolis D; Spreen WR; Cohen MS; McCauley M; Eron JJ
    PLoS Med; 2018 Nov; 15(11):e1002690. PubMed ID: 30408115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.